- Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
- Prothena Reports First Quarter 2024 Financial Results and Business Highlights
- Prothena to Report First Quarter 2024 Financial Results on May 8
- Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Key statistics
As of last trade Prothena Corporation PLC (PRTA:NSQ) traded at 20.17, 7.89% above its 52-week low of 18.69, set on Jun 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.69 |
---|---|
High | 20.79 |
Low | 20.11 |
Bid | 20.15 |
Offer | 20.18 |
Previous close | 20.26 |
Average volume | 432.22k |
---|---|
Shares outstanding | 53.77m |
Free float | 47.09m |
P/E (TTM) | -- |
Market cap | 1.09bn USD |
EPS (TTM) | -3.25 USD |
Data delayed at least 15 minutes, as of Jul 08 2024 16:11 BST.
More ▼